Intervention: Antagonist-induced Comparison: conventional Illustrative comparative risks* (95% CI) Outcomes Assumed risk Corresponding risk Relative effect (95% CI) No of Participants (studies) Quality of the evidence (GRADE) Comments conventional Antagonist-induced Medium risk population Number completing detoxification 576 per 1000 818 per 1000 (628 to 1060) RR 1.42 (1.09 to 1.84) 100 (2) ⊕⊕⊝⊝ low 1,2 Medium risk population Number commencing naltrexone maintenance treatment-Clonidine comparison 177 per 1000 758 per 1000 (515 to 1115) RR 4.28 (2.91 to 6.3) 240 (3) ⊕⊕⊕⊝ moderate 2 Medium risk population Number commencing naltrexone maintenance treatment-Buprenorphine comparison 730 per 1000 942 per 1000 (759 to 1168) RR 1.29 (1.04 to 1.6) 72 (1) ⊕⊕⊕⊝ moderate 2 Medium risk population Retained in naltrexone maintenance treatment or abstinent at 12 weeks-Tapered methadone comparison 333 per 1000 666 per 1000 (300 to 1482) RR 2 (0.9 to 4.45) 30 (1) ⊕⊕⊝⊝ low 1,2 Medium risk population Retained in naltrexone maintenance treatment or abstinent at 12 weeks-Clonidine comparison 88 per 1000 244 per 1000 (121 to 494) RR 2.77 (1.37 to 5.61) 240 (3) ⊕⊕⊕⊝ moderate 2 Cochrane Library Trusted evidence. Informed decisions. Better health.